Table 5 Multivariate Cox proportional hazard analysis of clinicopathological features and immunological markers with disease-free survival (DFS) and overall survival (OS) in 63 patients with LA-NPC at the time of presentation
DFS | OS | |||||
|---|---|---|---|---|---|---|
HR | 95% CI | *P | HR | 95% CI | P | |
Age | ||||||
< 40 years | 1 | 1 | ||||
≥ 40 years | 0.7 | 0.2–2.6 | 0.624 | 1.3 | 0.1–32.3 | 0.839 |
WHO type | ||||||
III | 1 | 1 | ||||
I & II | 1.5 | 0.4–4.8 | 0.516 | 0.2 | 0.0–1.3 | 0.094 |
UICC Stage | ||||||
III | 1 | |||||
IVa | 1.4 | 0.4–4.8 | 0.597 | 0.6 | 0.1–5.6 | 0.604 |
CD3+ TIL | ||||||
High | 1 | 1 | ||||
Low | 8 | 2.5–30.6 | < 0.001 | 17.5 | 2.1–434.0 | 0.006 |
FOXP3+/CD3+ TIL | ||||||
Low (≤ 10% of CD3 + TIL) | 1 | 1 | ||||
High (> 10% of CD3 + TIL) | 1.1 | 0.4–2.8 | 0.889 | 1.8 | 0.3–18.7 | 0.564 |
⋄ PD-1+/CD3+ TIL | ||||||
Low (< 10% of CD3 + TIL) | 1 | |||||
High (≥ 10% of CD3 + TIL) | 0.6 | 0.2–1.7 | 0.331 | 0.2 | 0–1.5 | 0.117 |
PD-L1 | ||||||
Positive (≥ 10%) | 1 | |||||
Negative (< 10%) | 1.3 | 0.4–3.8 | 0.672 | 5.6 | 1–49.6 | 0.054 |